Gevorg Grigoryan - 26 Feb 2026 Form 4 Insider Report for Generate Biomedicines, Inc. (GENB)

Reporting relationship: Chief Technology Officer
Issuer ticker: GENB
Reported as of: 26 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Mar 2026, 17:51:38 UTC
Source filing: View source filing
Reporting owner signature: /s/ Michael Wolf, Attorney-in-Fact

Key filing fact

Gevorg Grigoryan filed Form 4 for Generate Biomedicines, Inc. (GENB) on 02 Mar 2026.

Key facts

This page summarizes Gevorg Grigoryan's Form 4 filing for Generate Biomedicines, Inc. (GENB).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Mar 2026, 17:51.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002108976 Primary reporting owner

Grigoryan Gevorg

Relationship: Chief Technology Officer
Address: GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE
Signature: /s/ Michael Wolf, Attorney-in-Fact
Signature date: 02 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GENB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +295,608
Change %
Price: $0.000000
Shares after: 295,608
Date: 26 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 295,608
Exercise price: $16.00
Footnotes: F1

GENB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +196,368
Change %
Price: $0.000000
Shares after: 196,368
Date: 26 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 196,368
Exercise price: $16.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares underlying this option shall vest in two equal installments on each of February 19, 2029 and February 19, 2030, subject to the Reporting Person's continued service on each such vesting date.

Footnote F2

The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.